Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers

por de Vries, F., van Staa, T.-P., Leufkens, H. G. M.
Publicado 2010

Linking market authorizations of medicines with disease burden in South Africa

por Narsai, K., Leufkens, H. G. M., Mantel-Teeuwisse, A. K.
Publicado 2021

Variability in market uptake of psychotropic medications in Europe reflects cultural diversity

por Hoebert, J. M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., van Dijk, L.
Publicado 2017

Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the s...

por Minnema, L. A., Giezen, T. J., Egberts, T. C. G., Leufkens, H. G. M., Gardarsdottir, H.
Publicado 2020

Use of β-Blockers and the Risk of Hip/Femur Fracture in the United Kingdom and The Netherlands

por de Vries, F., Souverein, P. C., Cooper, C., Leufkens, H. G. M., van Staa, T. P.
Publicado 2007

Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries

por Bazargani, Y. T., Ugurlu, M., de Boer, A., Leufkens, H. G. M., Mantel-Teeuwisse, A. K.
Publicado 2018

Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study

por Pouwels, S., van Staa, T. P., Egberts, A. C. G., Leufkens, H. G. M., Cooper, C., de Vries, F.
Publicado 2009

Essential medicines for breast cancer in low and middle income countries

por Bazargani, Y. T., de Boer, A., Schellens, J. H. M., Leufkens, H. G. M., Mantel-Teeuwisse, Aukje K.
Publicado 2015

Impact of a global leader on pharmaceutical practice and policy around the world

por Alves da Costa, F., Henman, M., Hughes, C., Leufkens, H., Babar, Z., McElnay, J., Schulz, M.
Publicado 2020

Fracture rate in patients with myasthenia gravis: the general practice research database

por Pouwels, S., de Boer, A., Javaid, M. K., Hilton-Jones, D., Verschuuren, J., Cooper, C., Leufkens, H. G., de Vries, F.
Publicado 2012

Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study

por Pouwels, S., Lalmohamed, A., Souverein, P., Cooper, C., Veldt, B. J., Leufkens, H. G., de Boer, A., van Staa, T., de Vries, F.
Publicado 2010

Safety Experience During Real-World Use of Injectable Artesunate in Public Health Facilities in Ghana and Uganda: Outcomes of a Modified Cohort Event Monitoring Study (CEMISA)

por Ampadu, H. Hilda, Dodoo, Alexander N. O., Bosomprah, Samuel, Akakpo, Samantha, Hugo, Pierre, Gardarsdottir, Helga, Leufkens, H. G. M., Kajungu, Dan, Asante, Kwaku Poku
Publicado 2018

Risk of infections in patients with gout: a population-based cohort study

por Spaetgens, B., de Vries, F., Driessen, J. H. M., Leufkens, H. G., Souverein, P. C., Boonen, A., van der Meer, J. W. M., Joosten, L. A. B.
Publicado 2017

Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort

por Bours, S., de Vries, F., van den Bergh, J. P. W., Lalmohamed, A., van Staa, T. P., Leufkens, H. G. M., Geusens, P. P. P., Drent, M., Harvey, N. C.
Publicado 2015

Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010

por Klop, C., Gibson-Smith, D., Elders, P. J. M., Welsing, P. M. J., Leufkens, H. G. M., Harvey, N. C., Bijlsma, J. W. J., van Staa, T.-P., de Vries, F.
Publicado 2015

Use of anti-depressants and the risk of fracture of the hip or femur

por van den Brand, M. W. M., Samson, M. M., Pouwels, S., van Staa, T. P., Thio, B., Cooper, C., Leufkens, H. G. M., Egberts, A. C. G., Verhaar, H. J. J., de Vries, F.
Publicado 2009

Use of anti-depressants and the risk of fracture of the hip or femur

por van den Brand, M. W. M., Pouwels, S., Samson, M. M., van Staa, T. P., Thio, B., Cooper, C., Leufkens, H. G. M., Egberts, A. C. G., Verhaar, H. J. J., de Vries, F.
Publicado 2009

Long-term persistence with anti-osteoporosis drugs after fracture

por Klop, C., Welsing, P. M. J., Elders, P. J. M., Overbeek, J. A., Souverein, P. C., Burden, A. M., van Onzenoort, H. A. W., Leufkens, H. G. M., Bijlsma, J. W. J., de Vries, F.
Publicado 2015

“Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?

por Eichler, H‐G, Bloechl‐Daum, B, Bauer, P, Bretz, F, Brown, J, Hampson, LV, Honig, P, Krams, M, Leufkens, H, Lim, R, Lumpkin, MM, Murphy, MJ, Pignatti, F, Posch, M, Schneeweiss, S, Trusheim, M, Koenig, F
Publicado 2016

From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients

por Eichler, H‐G, Baird, LG, Barker, R, Bloechl‐Daum, B, Børlum‐Kristensen, F, Brown, J, Chua, R, Del Signore, S, Dugan, U, Ferguson, J, Garner, S, Goettsch, W, Haigh, J, Honig, P, Hoos, A, Huckle, P, Kondo, T, Le Cam, Y, Leufkens, H, Lim, R, Longson, C, Lumpkin, M, Maraganore, J, O'Rourke, B, Oye, K, Pezalla, E, Pignatti, F, Raine, J, Rasi, G, Salmonson, T, Samaha, D, Schneeweiss, S, Siviero, PD, Skinner, M, Teagarden, JR, Tominaga, T, Trusheim, MR, Tunis, S, Unger, TF, Vamvakas, S, Hirsch, G
Publicado 2015